

# Biosimilars

-a Canadian view

Anthony S Russell, Univ. Alberta, Canada

Biosimilars-formal approval after testing

Intended biosimilars:-en route to above

Biomimics:-not en route to formal testing prior to agency review

# Biosimilars-the Canadian perspective (at the present time)

- Non-medical switching while on established Rx not supported
- Postmarketing surveillance of all new biologics-incl.biosimilars
- All biologic products should be identified by appropriate naming
- In naïve individual choice between biosimilar/innovative mol can be considered
- Substitutions from one biologic to another-including biosimilars- should be by the treating physician
- Biosimilars and innovator molecules should have indications only where data is sufficient from clinical studies and where approved by the national regulatory agency

# EULAR 2017-biosimilars

Infliximab:-Inflectra=Remsima;SB2-Flixabi/Renflexis;  
BCD055-Biocad

Etanercept;Brenzys=Benpali;Erelzi(sand,)

Adalim:-Amgevita;Solymbic;SB5;Cadilla

Ritux:-Truxima;Rixathon

“Interchangeable”:-may be substituted for the reference product without the interaction of the healthcare provider.